Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TRVI 
Trevi Therapeutics Inc (TRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: TRVI (5-star) is a REGULAR-BUY. BUY since 45 days. Simulated Profits (24.85%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.6
1 Year Target Price $20.6
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 117.71% | Avg. Invested days 29 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.04B USD | Price to earnings Ratio - | 1Y Target Price 20.6 |
Price to earnings Ratio - | 1Y Target Price 20.6 | ||
Volume (30-day avg) 8 | Beta 0.72 | 52 Weeks Range 2.36 - 9.92 | Updated Date 09/19/2025 |
52 Weeks Range 2.36 - 9.92 | Updated Date 09/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.83% | Return on Equity (TTM) -35.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 836980341 | Price to Sales(TTM) - |
Enterprise Value 836980341 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.92 | Shares Outstanding 121776855 | Shares Floating 90633642 |
Shares Outstanding 121776855 | Shares Floating 90633642 | ||
Percent Insiders 0.72 | Percent Institutions 92.89 |
Upturn AI SWOT
Trevi Therapeutics Inc
Company Overview
History and Background
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduviou2122 (oral nalbuphine ER) for chronic cough in adults and pruritus (chronic itch). Founded to address unmet needs in chronic conditions, the company is headquartered in New Haven, Connecticut.
Core Business Areas
- Pharmaceutical Development: Focuses on the research and development of new drug candidates, particularly Haduvio, for chronic cough and pruritus.
- Clinical Trials: Manages and executes clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Plans for the future commercialization of its drug candidates upon regulatory approval.
Leadership and Structure
The leadership team includes key executives in areas such as research and development, clinical operations, and finance. The organizational structure is typical of a clinical-stage biotech company, emphasizing research and development.
Top Products and Market Share
Key Offerings
- Haduviou2122 (oral nalbuphine ER): Haduvio is the company's lead product candidate, an oral extended-release formulation of nalbuphine. It is in development for chronic cough in adults and pruritus. The company hopes to capture a significant portion of the pruritus market once approved. Competitors include other pharmaceutical companies working on therapies for chronic itch and cough, such as Cara Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and strong competition. There is a growing demand for novel therapies addressing unmet medical needs, like chronic cough and pruritus.
Positioning
Trevi Therapeutics is positioned as a company focusing on chronic cough and pruritus markets. Their competitive advantage relies on the Haduvio profile.
Total Addressable Market (TAM)
The TAM for chronic cough and pruritus is estimated to be significant, reaching billions of dollars. Trevi Therapeutics is positioned to capture a portion of this market with successful development and commercialization of Haduvio.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical needs
- Novel drug candidate (Haduvio)
- Experienced management team
Weaknesses
- Reliance on a single drug candidate
- High R&D costs
- No current revenue stream
- Small market capitalization
Opportunities
- Successful clinical trial results
- Regulatory approval of Haduvio
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from existing or new therapies
- Funding challenges
- Patent Challenges
Competitors and Market Share
Key Competitors
- CARA
- VNDA
- KALA
Competitive Landscape
Trevi Therapeutics faces competition from larger, more established pharmaceutical companies with greater resources. Its success depends on demonstrating the superior efficacy and safety of Haduvio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by increasing R&D investment and fluctuations in stock price based on clinical trial updates.
Future Projections: Future growth depends heavily on the successful development and commercialization of Haduvio. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Haduvio and efforts to secure funding for future development.
Summary
Trevi Therapeutics is a clinical-stage company with potential in the chronic cough and pruritus markets. Its success hinges on the clinical development and regulatory approval of Haduvio. The company faces challenges typical of early-stage biopharmaceutical firms, including funding and competition. Positive clinical data will drive success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Analyst reports, Industry databases
Disclaimers:
This analysis is based on available data and is not financial advice. Market share data is estimated and may not be precise. The AI-based rating is for informational purposes only and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevi Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2019-05-07 | Co-Founder, CEO, President, Interim Principal Financial Officer & Director Ms. Jennifer L. Good | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | |
Full time employees 33 | |||
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.